 |
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club |
J.-J Body, P. Bergmann, S. Boonen, Y. Boutsen, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster |
 |
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis |
R. Rizzoli, N. Burlet, D. Cahall, P. D. Delmas, E. F. Eriksen, D. Felsenberg, J. Grbic, M. Jontell, R. Landesberg, A. Laslop, M. Wollenhaupt, S. Papapoulos, O. Sezer, M. Sprafka, J.-Y. Reginster |
 |
The role of calcium and vitamin D in the management of osteoporosis |
R. Rizzoli, S. Boonen, M.-L. Brandi, N. Burlet, P. Delmas, J.-Y. Reginster |
 |
European regulatory perspectives for innovative therapies |
S. Ormarsdottir, J.-Y. Reginster, E. Abadie |
 |
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system |
O. Bruyère, N. Burlet, P. D. Delmas, R. Rizzoli, C. Cooper and J.-Y. Reginster |
 |
Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science |
J. Compston, D.M. Reid, J. Boisdron, M.-L. Brandi, N. Burlet, D. Cahall, P.D. Delmas, W. Dere, J.-P. Devogelaer, L.A. Fitzpatrick, B. Flamion, N. Goel, S. Korte, A. Laslop, B. Mitlak, S. Ormarsdottir, J. Ringe, R. Rizzoli, Y. Tsouderos, T. Van Staa, J.-Y. Reginster |
|
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women |
O. Bruyere, A. R. Varela, S. Adami, J. Detilleux, V. Rabenda, M. Hiligsmann, J.-Y. Reginster |
 |
Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity |
P. Musette, M. L. Brandi, P. Cacoub, J. M. Kaufman, R. Rizzoli, J.-Y. Reginster |
 |
Management of osteoporosis in the elderly |
R. Rizzoli, O. Bruyere, J. B. Cannata-Andia, J.-P. Devogelaer, G. Lyritis, J. D. Ringe, B. Vellas, J.-Y. Reginster |
 |
Post-fracture management of patients with hip fracture: a perspective |
O. Bruyere, M.-L. Brandi, N. Burlet, N. Harvey, G. Lyritis, H. Minne, S. Boonen, J.-Y. Reginster, R. Rizzoli and K. Akesson |
 |
European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli |
 |
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women |
V. Rabenda, R. Mertens, V. Fabri, J. Vanoverloop, F. Sumkay, C. Vannecke, A. Deswaef, G. A. Verpooten, J.-Y. Reginster |
 |
Adherence to treatment of osteoporosis: a need for study |
F. Lekkerkerker, J. A. Kanis, N. Alsayed, G. Bouvenot, N. Burlet, D. Cahall, A. Chines, P. Delmas, R.-L. Dreiser, D. Ethgen, N. Hughes, J.-M. Kaufman, S. Korte, G. Kreutz, A. Laslop, B. Mitlak, V. Rabenda, R. Rizzoli, A. Santora, R. Schimmer, Y. Tsouderos, P. Viethel, J.-Y. Reginster |
 |
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis |
J. Goldhahn, W. H. Scheele, B. Mitlak, E. Abadie, P. Aspenberg, P. Augat, M.-L. Brandi, N. Burlet, A. Chines, P. D. Delmas, I. Dupin-Roger, D. Ethgen, B. Hanson, F. Hartl, J. Kanis, R. Kewalramani, A. Laslop, D. Marsh, S. Ormarsdottir, R. Rizzoli, A. Santora, G. Schmidmaier, M. Wagener, J.-Y. Reginster |
 |
Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair |
J. Goldhahn, B. Mitlak P. Aspenberg, J. Kanis, R. Rizzoli, J.-Y. Reginster |
 |
Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture |
V. Rabenda, J. Vanoverloop, V. Fabri, R. Mertens, F. Sumkay, C. Vannecke, A. Deswaef, G. A. Verpooten, J.-Y. Reginster |
 |
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence |
V. Rabenda, M. Hiligsmann, J.-Y. Reginster |
 |
Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures |
V. Rabenda, J.-Y. Reginster |
 |
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men |
J.-Y. Reginster, E. Abadie, P. Delmas, R. Rizzoli, W. Dere, P. der Auwera, B. Avouac, M.-L. Brandi, A. Daifotis, A. Diez-Perez, G. Calvo, O. Johnell, J.-M. Kaufman, G. Kreutz, A. Laslop, F. Lekkerkerker, B. Mitlak, P. Nilsson, J. Orloff, M. Smillie, A. Taylor, Y. Tsouderos, D. Ethgen, B. Flamion |
 |
Therapeutic Adherence with Bisphosphonates in the Treatment of Osteoporosis |
V. Rabenda, J.-Y. Reginster |
 |
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women |
O. Bruyere, A. R. Varela, S. Adami, J. Detilleux,V. Rabenda, M. Hiligsmann, J.-Y. Reginster |